Clinical Trial Update: Biomarker Research Study for PF-03084014 in cHEmoresistant Triple-negative Breast cAncer [Phase 2]

View source ↗

Summary

A Phase 2 biomarker study of PF-03084014 in chemoresistant triple-negative breast cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• PF-03084014 (nirogacestat)

Snippet

Sponsor: Jules Bordet Institute | Conditions: Breast Cancer | Phase 2 | Status: WITHDRAWN